These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33049114)

  • 21. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force.
    Aisen PS; Siemers E; Michelson D; Salloway S; Sampaio C; Carrillo MC; Sperling R; Doody R; Scheltens P; Bateman R; Weiner M; Vellas B
    J Prev Alzheimers Dis; 2018; 5(3):171-174. PubMed ID: 29972209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Verubecestat for Prodromal Alzheimer's Disease.
    Li S; Liu L; Selkoe D
    N Engl J Med; 2019 Jul; 381(4):388. PubMed ID: 31340105
    [No Abstract]   [Full Text] [Related]  

  • 24. Verubecestat for Prodromal Alzheimer's Disease. Reply.
    Kennedy ME; Egan MF
    N Engl J Med; 2019 Jul; 381(4):389. PubMed ID: 31340106
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
    Grove RA; Harrington CM; Mahler A; Beresford I; Maruff P; Lowy MT; Nicholls AP; Boardley RL; Berges AC; Nathan PJ; Horrigan JP
    Curr Alzheimer Res; 2014 Jan; 11(1):47-58. PubMed ID: 24359500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Model-Based Approach to Bridging Plasma and Dried Blood Spot Concentration Data for Phase 3 Verubecestat Trials.
    Dockendorf MF; Jaworowicz D; Humphrey R; Anderson M; Breidinger S; Ma L; Taylor T; Dupre N; Jones C; Furtek C; Kantesaria B; Bateman KP; Woolf E; Egan MF; Stone JA
    AAPS J; 2022 Apr; 24(3):53. PubMed ID: 35384522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
    Le Bars PL
    Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.
    Thaisrivongs DA; Miller SP; Molinaro C; Chen Q; Song ZJ; Tan L; Chen L; Chen W; Lekhal A; Pulicare SK; Xu Y
    Org Lett; 2016 Nov; 18(22):5780-5783. PubMed ID: 27934506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.
    Decourt B; Drumm-Gurnee D; Wilson J; Jacobson S; Belden C; Sirrel S; Ahmadi M; Shill H; Powell J; Walker A; Gonzales A; Macias M; Sabbagh MN
    Curr Alzheimer Res; 2017; 14(4):403-411. PubMed ID: 28124585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
    Mecocci P; Bladström A; Stender K
    Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.
    Cebers G; Alexander RC; Haeberlein SB; Han D; Goldwater R; Ereshefsky L; Olsson T; Ye N; Rosen L; Russell M; Maltby J; Eketjäll S; Kugler AR
    J Alzheimers Dis; 2017; 55(3):1039-1053. PubMed ID: 27767991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective Secretase Targeting for Alzheimer's Disease Therapy.
    Miranda A; Montiel E; Ulrich H; Paz C
    J Alzheimers Dis; 2021; 81(1):1-17. PubMed ID: 33749645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
    Lu L; Zheng X; Wang S; Tang C; Zhang Y; Yao G; Zeng J; Ge S; Wen H; Xu M; Guyatt G; Xu N
    J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1316-1324. PubMed ID: 33046560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
    Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
    Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.